Family functionality, medication adherence, and blood glucose control among ambulatory type 2 diabetic patients in a primary care clinic in Nigeria

2018 ◽  
Vol 7 (1) ◽  
pp. 23
Author(s):  
GabrielUche Pascal Iloh ◽  
PeaceIfeoma Collins ◽  
AgwuNkwa Amadi
Keyword(s):  
Primary Care ◽  
Blood Glucose ◽  
Blood Glucose Control ◽  
Primary Care Clinic ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Care Clinic ◽  
Family Functionality ◽  
Type 2 Diabetic

Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients

Drug Research ◽  
2018 ◽  
Vol 68 (12) ◽  
pp. 669-672
Author(s):  
Masataka Kusunoki ◽  
Yukie Natsume ◽  
Tetsuro Miyata ◽  
Kazuhiko Tsutsumi ◽  
Yoshiharu Oshida
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Hemoglobin A1c ◽  
Blood Glucose Control ◽  
Sglt2 Inhibitor ◽  
Serum Triglyceride ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

AbstractIn patients with type 2 diabetes mellitus who show suboptimal blood glucose control under insulin therapy alone, concomitant treatment with an additional hypoglycemic agent that differs in its mechanism of action from insulin may be considered. We conducted this clinical trial to explore whether further control of increased blood glucose level can be achieved with concomitant use of sodium glucose co-transporter 2 (SGLT2) inhibitor as concomitant with other hypoglycemic therapy, as compared to SGLT2 inhibitor monotherapy, in patients with type 2 diabetes mellitus showing decrease in blood glucose level but less than the effect of insulin monotherapy and there was no significant differences. In the SGLT2 inhibitor monotherapy group, decreases of the serum hemoglobin A1c (HbA1c) level, body weight, body mass index (BMI) and serum triglyceride, and elevation of the serum high density lipoprotein cholesterol concentration were observed as compared to the baseline values. In the type 2 diabetic patients under insulin therapy who received combined insulin plus SGLT2 inhibitor therapy, however decreases in the body weight and BMI, with only a tendency towards decrease of the serum HbA1c value, not reaching statistical significance, were observed. The combined therapy group also showed no appreciable changes of the serum triglyceride level, while the serum adiponectin level increased. The present study data indicate that combined insulin plus SGLT2 inhibitor treatment failed to afford any further improvement of the blood glucose control, as compared to SGLT2 monotherapy, in Japanese type 2 diabetic patients.

Improved Blood Glucose Control by Insulin Therapy in Type 2 Diabetic Patients Has No Effect on Lipoprotein(a) Levels

1993 ◽  
Vol 10 (5) ◽  
pp. 427-430 ◽  
Author(s):  
B.H.R. Wolffenbuttel ◽  
P.B. Leurs ◽  
J.P.J.E. Sels ◽  
G.J.W.M. Rondas-Colbers ◽  
P.P.C.A. Menheere ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Insulin Therapy ◽  
Glucose Control ◽  
Blood Glucose Control ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Lipoprotein A ◽  
Type 2 Diabetic

scholarly journals Glycemic Status of Type 2 Diabetic Patients Treated with Different Single Anti-diabetic Agents

2016 ◽  
Vol 5 (2) ◽  
pp. 92-97
Author(s):  
Sultana Marufa Shefin ◽  
Nazmul Kabir Qureshi ◽  
Sazzad Hossain Khandker ◽  
Faria Afsana ◽  
Omar Faruque ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Blood Glucose Control ◽  
Age Groups ◽  
Diabetic Patients ◽  
Glycemic Status ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Glucose Profiles ◽  
Type 2 Diabetic

Objective: The study was aimed to describe the patterns of single anti-diabetic agents used by type 2 diabetic patients and their glycemic status during hospital admission.Study design and methods: This cross-sectional study was carried out in BIRDEM among hospitalized type 2 adult diabetic patients of different ages and both sexes. Data were collected during admission that included detailed history, medical records review, clinical examination and laboratory investigations.Results: Subjects (n=253; 174 female, 79 male) had age (years) as mean ± SD: 55.28 ±13.45 (15- 90 years), BMI (kg/m2) as mean ±SD: 24.67±4.97 and HbA1c (%) as mean ±SD: 10.56±2.98. Use of pre-mixed insulin 90 (35.57%) and split-mixed insulin 70 (27.66%) were more common than other drugs. Glycaemic control was poor in all age groups as evidenced by raised HbA1c, significantly higher in patients <40 years age group. Blood glucose profiles were also high among the all age groups. HbA1c and blood glucose profiles both were high irrespective of type of anti-diabetic agents used during admission. It was also found that patients with increasing age groups were using insulin more frequently. BMI categorization had no significance within treatment groups. (p=0.453).Conclusion: There was no significant difference in blood glucose control among the different single anti-diabetic drug users, that might be due to treatment of diabetes includes medical nutrition therapy with judicious and individualized dietary plan, lifestyle modification, effective exercise plan, and individualized target oriented use of anti-diabetic agents. Along with proper selection of anti-diabetic agents, patient’s self-management education and disease-specific awareness is essential to achieve good glycemic control.Birdem Med J 2015; 5(2): 92-97

Sign in / Sign up

Export Citation Format

Share Document